GlobeImmune drug shows promise
Last Updated: 15:36 March 28, 2012
LOUISVILLE - A vaccine from Louisville-based GlobeImmune Inc. showed promise in treating Hepatitis C in its latest patient trial, the biotechnology company said Saturday in a statement.
The company's Tarmogen product for Hepatitis C showed "improved response" from 12 percent of patients in the study with the chronic Hepatitis C virus, the company said. The company also is testing a drug to treat pancreatic cancer and nonsmall cell lung cancer.
"In this study, GI-5005 (the drug) conferred a three-fold improvement in SVR (sustained virologic response) - an important treatment effect in this challenging patient population," said Doctor Paul J. Pockros of Scripps Clinic in San Diego, Calif., which led the study.
An additional 40 patients with a specific type of Hepatitis C were added to the study last week, the company said.
Privately-held GlobeImmune received $40 million in May 2009 as part of a new partnership with Celgene Corp. in Summit, New Jersey. The two companies said they would work jointly on multiple products to treat cancer.
The company has about 40 employees. In January, GlobeImmune said it had closed on a round of financing for $18 million.
More breaking news...
Single-family residential listings decline
Solera sets date for shareholder meeting
EKS&H bolsters services through aquisition
Solera National Bancorp (OTCQB: SLRK), is the holding company for Solera National Bank, which has a mortgage origination